Breast Neoplasms, Medication Adherence
Conditions
Keywords
Administrative Claims, Healthcare, Aromatase Inhibitors, Breast Neoplasms, Health Services for the Aged, Medical Informatics Applications, Medication Adherence, Outcome and Process Assessment (Health Care), Selective Estrogen Receptor Modulators, Telemedicine
Brief summary
Background: In women with hormone receptor positive (HR+) breast cancer, adjuvant endocrine therapy (AET) is associated with a significant survival advantage. Nonadherence is a particular challenge in older women, even though they stand to benefit the most from AET. Therefore, a novel e-health tool (OPTIMUM) that integrates real-time analysis of health administrative claims data was developed to provide point-of-care decision support for clinicians.
Detailed description
Objectives: 1) To determine the effectiveness of a patient-specific, real-time e-health alerts delivered at point-of-care in reducing rates of AET discontinuation and to understand patient-level factors related to AET discontinuation. 2) To assess integration of e-health alerts regarding deviations from best practices in administration of AET by cancer care teams. Methods: A prospective, two group controlled comparison pilot study will be conducted at two urban, McGill University-affiliated hospitals, the Royal Victoria Hospital and St. Mary's Hospital. A minimum of 43 patients per study arm will be enrolled through site-level allocation. Follow-up is 1.5 years. Healthcare professionals at the intervention site will have access to the e-health tool which will report to them in real-time: medical events with known associations to AET discontinuation, AET adherence monitor, and a discontinuation alert.
Interventions
OTHEROPTIMUM e-health tool
If you are treated in a hospital that is using the OPTIMUM e-health tool (intervention group), once your care team receives any alerts, they may choose to: * Contact you over the phone or in person to provide medical advice on how to better take your pills, * Contact your pharmacist(s) and other doctors about your anti-cancer treatment.
Sponsors
McGill University Health Centre/Research Institute of the McGill University Health Centre
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
FEMALE
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Must be ≥ 65 years old, 2. Have been diagnosed with incident (non-metastatic) breast cancer, 3. Have a histologically-confirmed breast adenocarcinoma, 4. Have undergone breast surgery for stages I-III disease, 5. Have medical insurance with the Régie de l'Assurance Maladie du Québec (RAMQ) for at least 1 year prior to surgery, 6. Have HR positive disease, 7. Have no history of AET use prior to the diagnosis of breast cancer, 8. Expected to initiate AET or have only recently initiated AET (\<6 months) but are free of previous discontinuation events, 9. Have the ability to consent for herself.
Exclusion criteria
male gender
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients discontinuing adjuvant endocrine therapy treatment | 1.5 years | In each trial arm, the proportion of patients discontinuing AET treatment will be calculated as the number of patients discontinuing AET treatment divided by the total number of patients in that trial arm. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients re-initiating after a discontinuation of adjuvant endocrine therapy treatment | 1.5 years | In each trial arm, the proportion of patients re-initiating after a discontinuation of AET treatment will be calculated as the number of patients who start taking AET after a period of stopping divided by the total number of patients that discontinued in that trial arm. |
| Mean time to adjuvant endocrine therapy treatment re-initiation. | 1.5 years | In each trial arm, mean time to AET treatment re-initiation will be calculated as the average number of days for a patient who has stopped taking AET treatment to start again, among those who start again (re-initiate). |
| Medical Possession Ratio ≥80% | 1.5 years | In each trial arm, the proportion of patients that maintain a Medical Possession Ratio ≥80% will be calculated as the proportion patients whose proportion of number of days covered by medication supply in the treatment period is ≥80%. |
| Cancer Care Team Actions in the intervention arm - perform telephone follow-up with patient | 1.5 years | Upon alert receipt that a patient is at risk of discontinuing adjuvant endocrine therapy treatment or has discontinued AET treatment, for that patient, if a member of the cancer care team called the patient will be assessed qualitatively (yes/no) and quantitatively (if yes, time in number of days before the patient was called). |
| Cancer Care Team Actions in the intervention arm - perform telephone follow-up with community pharmacist | 1.5 years | Upon alert receipt that a patient is at risk of discontinuing adjuvant endocrine therapy treatment or has discontinued AET treatment, for that patient, if a member of the cancer care team called the patient's pharmacist will be assessed qualitatively (yes/no) and quantitatively (if yes, time in number of days before the patient's pharmacist was called). |
| Cancer Care Team Actions in the intervention arm - arrange for return to clinic with doctor | 1.5 years | Upon alert receipt that a patient is at risk of discontinuing adjuvant endocrine therapy treatment or has discontinued AET treatment, for that patient, if a member of the cancer care team arranged for the patient to return to the clinic to see the doctor will be assessed qualitatively (yes/no) and quantitatively (if yes, time in number of days before the cancer care team arranged a return to clinic with doctor). |
| Primary Non-adherence | 1.5 years | In each trial arm, the proportion of patients who are prescribed AET treatment but do not fill any prescriptions will be calculated as the number of patients with primary non-adherence divided by the total number of patients in that trial arm. |
| Cancer Care Team Actions in the intervention arm - referral to doctor for closer follow-up | 1.5 years | Upon alert receipt that a patient is at risk of discontinuing adjuvant endocrine therapy treatment or has discontinued AET treatment, for that patient, if a member of the cancer care team referred the patient to a doctor will be assessed qualitatively (yes/no) and quantitatively (if yes, time in number of days before the cancer care team referred the patient to a doctor). Note that this action is different than the outcome arrange for return to clinic with doctor because this outcome occurs when a nurse directly schedules a patient to see a specific doctor without discussing with a doctor first. |
| Cancer Care Team Actions in the intervention arm - referral to cancer nurse for closer follow-up | 1.5 years | Upon alert receipt that a patient is at risk of discontinuing adjuvant endocrine therapy treatment or has discontinued AET treatment, for that patient, if a member of the cancer care team referred the patient to a cancer nurse will be assessed qualitatively (yes/no) and quantitatively (if yes, time in number of days before the cancer care team referred the patient to a cancer nurse). |
| Cancer Care Team Actions in the intervention arm - ignore the alert | 1.5 years | Upon alert receipt that a patient is at risk of discontinuing adjuvant endocrine therapy treatment, for that patient, if no action by the cancer care team was taken will be assessed qualitatively (yes/no) and quantitatively (how many alerts per patient were ignored). Note that ignore the alert is an explicit option that care teams can specify. They will be trained to understand that the ignore the alert option represents that the patient has not discontinued AET treatment and that they are of the opinion that the patient is not at risk of discontinuing AET treatment despite reading the alert. |
| Cancer Care Team Actions in the intervention arm - no changes in usual treatment despite new information provided | 1.5 years | Upon alert receipt that a patient is at risk of discontinuing adjuvant endocrine therapy treatment or has discontinued AET treatment, for that patient, if no changes by the cancer care team were taken will be assessed qualitatively (yes/no) and quantitatively (how many alerts per patient were ignored). Note that this no changes is an explicit option that care teams can specify. They will be trained to understand that the no changes option represents that the patient requires other considerations beyond adhering to AET such as is stopping AET for upcoming surgery or no longer is indicated for AET based on disease progression (for e.g., brain metastases). |
| Cancer Care Team Actions in the intervention arm - Other | 1.5 years | Any care team action that cannot be described by the predefined actions will be described by the care team in a free-text field for subsequent qualitative analysis. An overall theme or logical grouping of these qualitative outcomes will be explored and reported upon. |
| Cancer Care Team Actions in the intervention arm - arrange for return to clinic with nurse | 1.5 years | Upon alert receipt that a patient is at risk of discontinuing adjuvant endocrine therapy treatment or has discontinued AET treatment, for that patient, if a member of the cancer care team arranged for the patient to return to the clinic to see the nurse will be assessed qualitatively (yes/no) and quantitatively (if yes, time in number of days before the cancer care team arranged a return to clinic with nurse). |
Countries
Canada
Contacts
Primary ContactAri N Meguerditchian, MD
Outcome results
None listed